A Longitudinal Analysis of Chlamydial Infection and Trachomatous Inflammation Following Mass Azithromycin Distribution.


Journal

Ophthalmic epidemiology
ISSN: 1744-5086
Titre abrégé: Ophthalmic Epidemiol
Pays: England
ID NLM: 9435674

Informations de publication

Date de publication:
02 2019
Historique:
pubmed: 29 8 2018
medline: 8 3 2019
entrez: 29 8 2018
Statut: ppublish

Résumé

Mass azithromycin distributions are effective for clearing ocular strains of Chlamydia trachomatis, yet infection frequently returns in areas with hyperendemic trachoma. A better understanding of the factors associated with chlamydial reinfection could be helpful to plan trachoma elimination strategies. This was a prospective cohort study conducted in a trachoma-hyperendemic region of Ethiopia in 2003. As part of a larger cluster-randomized trial, 21 villages were treated with a single mass azithromycin distribution and all children 5 years and younger were monitored for ocular chlamydia and clinically active trachoma at baseline and at 2 and 6 months following the treatment. In 20 villages with available data, azithromycin treatment coverage was 88.7% (95% confidence interval [CI] 85.7-91.8%). In total, 1005 children tested negative for ocular chlamydia at the 2-month visit, of whom 41 became infected by 6 months (1.0 incident chlamydia infections per 100 person-months, 95%CI 0.7-1.4). The presence of intense trachomatous inflammation (TI) at baseline was associated with incident infection at 6 months (incidence rate ratio 1.91, 95%CI 1.03-3.55). Ocular chlamydia infections clustered more within households than communities: (intraclass correlation coefficient 0.01 for communities and 0.29 for households six months posttreatment). Younger children were more likely to have persistent clinically active trachoma (P = 0.03). More intensive antibiotic distributions may be warranted for younger children, for children with TI, and for households containing children with ocular chlamydia infections.

Sections du résumé

BACKGROUND
Mass azithromycin distributions are effective for clearing ocular strains of Chlamydia trachomatis, yet infection frequently returns in areas with hyperendemic trachoma. A better understanding of the factors associated with chlamydial reinfection could be helpful to plan trachoma elimination strategies.
METHODS
This was a prospective cohort study conducted in a trachoma-hyperendemic region of Ethiopia in 2003. As part of a larger cluster-randomized trial, 21 villages were treated with a single mass azithromycin distribution and all children 5 years and younger were monitored for ocular chlamydia and clinically active trachoma at baseline and at 2 and 6 months following the treatment.
RESULTS
In 20 villages with available data, azithromycin treatment coverage was 88.7% (95% confidence interval [CI] 85.7-91.8%). In total, 1005 children tested negative for ocular chlamydia at the 2-month visit, of whom 41 became infected by 6 months (1.0 incident chlamydia infections per 100 person-months, 95%CI 0.7-1.4). The presence of intense trachomatous inflammation (TI) at baseline was associated with incident infection at 6 months (incidence rate ratio 1.91, 95%CI 1.03-3.55). Ocular chlamydia infections clustered more within households than communities: (intraclass correlation coefficient 0.01 for communities and 0.29 for households six months posttreatment). Younger children were more likely to have persistent clinically active trachoma (P = 0.03).
CONCLUSIONS
More intensive antibiotic distributions may be warranted for younger children, for children with TI, and for households containing children with ocular chlamydia infections.

Identifiants

pubmed: 30153085
doi: 10.1080/09286586.2018.1512635
pmc: PMC6344262
mid: NIHMS1514727
doi:

Substances chimiques

Anti-Bacterial Agents 0
Azithromycin 83905-01-5

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

19-26

Subventions

Organisme : NEI NIH HHS
ID : R01 EY025350
Pays : United States
Organisme : NIMH NIH HHS
ID : R25 MH083620
Pays : United States
Organisme : NEI NIH HHS
ID : U10 EY016214
Pays : United States
Organisme : NEI NIH HHS
ID : U10 EY023939
Pays : United States

Références

Invest Ophthalmol Vis Sci. 2005 Jan;46(1):83-7
pubmed: 15623758
Ophthalmic Epidemiol. 2015;22(3):162-9
pubmed: 26158573
Invest Ophthalmol Vis Sci. 2014 Apr 11;55(4):2307-14
pubmed: 24448262
Int J Epidemiol. 1989 Dec;18(4):944-51
pubmed: 2621031
Lancet. 2005 Oct 8;366(9493):1296-300
pubmed: 16214600
Br J Ophthalmol. 1994 Nov;78(11):813-7
pubmed: 7848974
JAMA. 2008 Feb 20;299(7):778-84
pubmed: 18285589
Trans R Soc Trop Med Hyg. 2005 Jan;99(1):6-12
pubmed: 15550255
PLoS Negl Trop Dis. 2011 Dec;5(12):e1441
pubmed: 22180804
JAMA. 2006 Mar 8;295(10):1142-6
pubmed: 16522834
Trans R Soc Trop Med Hyg. 2005 Mar;99(3):218-25
pubmed: 15653125
Invest Ophthalmol Vis Sci. 1993 Oct;34(11):3194-8
pubmed: 8407229
PLoS Negl Trop Dis. 2008;2(12):e341
pubmed: 19048024
Lancet. 2005 Apr 9-15;365(9467):1321-8
pubmed: 15823382
PLoS Negl Trop Dis. 2011 Mar 15;5(3):e978
pubmed: 21423645
PLoS Negl Trop Dis. 2014 Apr 10;8(4):e2761
pubmed: 24722392
Int J Epidemiol. 1988 Dec;17(4):865-9
pubmed: 3265700
Am J Epidemiol. 2018 Sep 1;187(9):1840-1845
pubmed: 29617922
Invest Ophthalmol Vis Sci. 2014 Jun 06;55(7):4144-50
pubmed: 24906862
Int J Epidemiol. 1991 Dec;20(4):1088-92
pubmed: 1800408
PLoS Negl Trop Dis. 2009;3(2):e376
pubmed: 19190781
N Engl J Med. 2004 Nov 4;351(19):1962-71
pubmed: 15525721
Ophthalmic Epidemiol. 2004 Jul;11(3):255-62
pubmed: 15370556
Invest Ophthalmol Vis Sci. 2006 Jan;47(1):99-104
pubmed: 16384950
JAMA. 2004 Aug 11;292(6):721-5
pubmed: 15304470
Trop Med Int Health. 2008 Apr;13(4):556-65
pubmed: 18282237
Lancet. 1999 Aug 21;354(9179):630-5
pubmed: 10466664
Lancet. 2003 Jul 19;362(9379):198-204
pubmed: 12885481
Ophthalmic Epidemiol. 2001 Jul;8(2-3):109-17
pubmed: 11471080
Epidemiol Infect. 1999 Dec;123(3):479-86
pubmed: 10694161
Bull World Health Organ. 1987;65(4):477-83
pubmed: 3500800

Auteurs

Daniel P Morberg (DP)

a Francis I. Proctor Foundation , University of California , San Francisco , CA , USA.

Wondu Alemayehu (W)

b Orbis International , Addis Ababa , Ethiopia.

Muluken Melese (M)

b Orbis International , Addis Ababa , Ethiopia.

Takele Lakew (T)

b Orbis International , Addis Ababa , Ethiopia.

Alemayehu Sisay (A)

b Orbis International , Addis Ababa , Ethiopia.

Zhaoxia Zhou (Z)

a Francis I. Proctor Foundation , University of California , San Francisco , CA , USA.

Vicky Cevallos (V)

a Francis I. Proctor Foundation , University of California , San Francisco , CA , USA.

Catherine E Oldenburg (CE)

a Francis I. Proctor Foundation , University of California , San Francisco , CA , USA.

Travis C Porco (TC)

a Francis I. Proctor Foundation , University of California , San Francisco , CA , USA.
c Department of Ophthalmology , University of California , San Francisco , USA.
d Department of Epidemiology & Biostatistics , University of California , San Francisco , USA.
e Institute for Global Health , University of California , San Francisco , USA.

Thomas M Lietman (TM)

a Francis I. Proctor Foundation , University of California , San Francisco , CA , USA.
c Department of Ophthalmology , University of California , San Francisco , USA.
d Department of Epidemiology & Biostatistics , University of California , San Francisco , USA.
e Institute for Global Health , University of California , San Francisco , USA.

Jeremy D Keenan (JD)

a Francis I. Proctor Foundation , University of California , San Francisco , CA , USA.
c Department of Ophthalmology , University of California , San Francisco , USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH